Assessing the Evidence: Are We Initiating HBV Therapy Early Enough?

Comprehensive Summary: "Assessing the Evidence: Are We Initiating HBV Therapy Early Enough?"

Presenter: Douglas T. Dieterich, MD

1. Main Clinical Topics Discussed

• Global and U.S. hepatitis B virus (HBV) elimination goals and screening recommendations
• Limitations of current international HBV treatment guidelines
• Evidence supporting earlier initiation of antiviral therapy
• HBV DNA integration as a direct carcinogenic mechanism
• Cost-effectiveness of a "test and treat" strategy

2. Key Learning Points, Guidelines, and Recommendations

WHO 2030 Elimination Targets:

• 90% of infants receive birth-dose vaccination
• 100% of blood donations screened
• 90% access to safe injections
• 90% of infected individuals aware of status
• 80% of eligible patients treated
• The U.S. is currently performing poorly relative to these benchmarks

CDC Universal Screening Recommendations (recent):

• Test all adults at least once
• Test at-risk persons periodically
• Test any person requesting screening
• Test all pregnant women
• Screening requires all three tests: HBsAg, HBsAb, and HBcAb (now available as a single-order panel)

Critique of Current Treatment Guidelines (AASLD 2018, EASL 2017, APASL 2015):

• Guidelines based primarily on ALT elevation are inadequate
• ~40% of patients fall into an indeterminate phase not captured by current staging boxes
• HBV does not follow discrete phase boundaries; it is a continuous biological variable
• Guidelines fail to prevent a substantial proportion of HCC cases:

- 33% of HCC cases fell outside EASL treatment criteria

- 46% fell outside AASLD 2018 criteria

- 64% fell outside APASL 2015 criteria

Proposed Simplified Treatment Criteria (published in *Gastro Hep Advances*, 2024):

• Treat if: age ≥30 AND HBV DNA >2,000 IU/mL — regardless of ALT, AST, HBeAg, or HBeAb status
• Defer if: age <30 AND DNA <2,000 IU/mL — unless risk factors are present (significant fibrosis, family history of HCC, extrahepatic manifestations)
• Rationale: Age 30 aligns with WHO criteria; HCC development typically requires ~30 years of infection

3. Specific Clinical Data and Study Results Cited

Universal Screening Impact (per 100 persons screened):

• Prevention of 7 cases of compensated cirrhosis, 3 decompensated cirrhosis, 6 HCC cases, 2 liver transplants, and 10 HBV-related deaths

REVEAL Study (Taiwan) — HBV DNA and HCC Risk:

• HBV DNA >2,000 IU/mL (>10,000 copies/mL) significantly increases liver-related mortality in a cohort of ~22,000 patients
• So-called "inactive carriers" demonstrated measurable cumulative HCC incidence
• Indeterminate-phase patients had an 18-fold higher risk of HCC development

Immune-Tolerant Phase — Morbidity Data (n=413, no cirrhosis, normal ALT):

• 10-year HCC risk: 13% untreated vs. 6% treated (2.5× increased risk untreated)
• 10-year risk of death or liver transplantation: ~10% untreated vs. ~3.5% treated (~3× increased risk)

T-Cell Activation Study (Kennedy et al., Royal Free London):

• PD-1-positive CD8+ T cells are equally activated in so-called immune-tolerant and immune-active patients
• T-cell activation increases with age regardless of HBV phase, refuting the concept of true immune tolerance

Early Treatment — HCC Risk Reduction (Taiwan/U.S. Combined Cohort, n=2,200):

• Antiviral treatment associated with a 77% reduction in HCC risk (highly statistically significant)
• HCC risk is not eliminated;